Stanford University at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Stanford University brings 8 presentations to ASH 2026 in New Orleans. Its program leans toward artificial intelligence and cell therapy, including AI models that predict and engineer CAR T cell function and the risks of generative AI. It also covers pediatric AML treatment and the link between clonal hematopoiesis and arterial blood clots.
| Organization | ASH 2026 Attendance |
|---|---|
Stanford University Stanford, CA | |
Private research university in Stanford, California, including its School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. Session AI Models of Cell State for the Design of Next-Generation T Cell Therapies Using AI trained on patient data to predict which T cell states make CAR-T therapy work, moving cell design beyond trial and error. Talk Clinically Informed AI Models for Predicting and Engineering CAR T Cell Function Predicting which lymphoma patients respond to CAR-T from single-cell RNA profiles of the infused cells, then simulating better designs on a computer. Talk New Standards in GVHD Prophylaxis: Towards a Future Without GVHD Newer ways to prevent graft-versus-host disease after donor transplants, such as engineered cell grafts, abatacept, and post-transplant cyclophosphamide. Talk Clonal Hematopoiesis of Indeterminate Potential and Arterial Thrombosis: Mechanisms and Clinical Implications How clonal hematopoiesis alters myeloid cells to promote atherosclerosis, and how to evaluate affected patients for heart attack and stroke risk. Session From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis How clonal hematopoiesis, the age-related spread of mutated blood cells, fuels inflammation and artery and vein clots, and whether anti-inflammatory drugs help. Talk Targeted Therapies: From Genomic Insights to Therapeutic Strategies Genomic insights behind three targeted drug classes for childhood acute myeloid leukemia: blockers of B-cell lymphoma 2, menin and fms-like tyrosine kinase 3. Talk Treatment Sequencing After CAR-T Failure in Multiple Myeloma Choosing the next treatment for multiple myeloma that relapses after CAR-T cell therapy, weighing key clinical factors and approved and emerging options. Session Showcasing a Decade of Discoveries in Blood Advances Ten years of the hematology journal Blood Advances, revisiting its most influential clinical trials, basic science studies and practice guidelines. Talk Limitations and Risks of Generative AI Where generative AI fails in medicine, from hallucinations and bias to rare-disease blind spots, and how validation, governance, and human oversight reduce harm. Session Session Session Session |
Instantly find 20 buyers from Stanford University
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction